Dusigitumab

N/A

Report date: 2024/06/28 20:00:53

Base Information

Drug NameDusigitumab
Drug Alias Name度司妥单抗多塞妥人单抗MEDI-573
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionInsulin-like growth factor I inhibitorsInsulin-like growth factor II inhibitors
TargetsInsulin-like growth factor IIInsulin-like growth factor I
Therapy Area/IndicationsSolid tumoursBreast NeoplasmsCarcinoma, Hepatocellular +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBahamasBelgiumCanada +[12] 
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesMedimmune Llc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAstrazeneca PlcMedimmune Llc
Active IndicationsN/A
Inactive IndicationsSolid tumoursBreast NeoplasmsCarcinoma, Hepatocellular +[4] 

Other Information

ATC CodeN/A
Related LinksWikipediaKEGG